Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1994 1
1995 2
1996 1
1998 1
1999 5
2000 3
2001 3
2002 4
2003 5
2004 6
2005 8
2006 11
2007 18
2008 26
2009 18
2010 28
2011 24
2012 24
2013 37
2014 33
2015 30
2016 26
2017 14
2018 13
2019 14
2020 10
2021 11
2022 5
2023 4
2024 4
2025 6
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

368 results

Results by year

Filters applied: . Clear all
Page 1
Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review.
Duarte Lau F, Giugliano RP. Duarte Lau F, et al. JAMA Cardiol. 2022 Jul 1;7(7):760-769. doi: 10.1001/jamacardio.2022.0987. JAMA Cardiol. 2022. PMID: 35583875 Review.
These findings have led to the formulation of the Lp(a) hypothesis, namely that Lp(a) lowering leads to cardiovascular risk reduction, intensifying the search for Lp(a)-reducing therapies. The ineffectiveness of lifestyle modification, statins, and ezetimibe to lower Lp(a) …
These findings have led to the formulation of the Lp(a) hypothesis, namely that Lp(a) lowering leads to cardiovascular risk reduction …
Epidemiology and management of hyperlipidemia.
Karr S. Karr S. Am J Manag Care. 2017 Jun;23(9 Suppl):S139-S148. Am J Manag Care. 2017. PMID: 28978219 Free article. Review.
Statins are the mainstay treatment for hyperlipidemia; however, the limitations of statins include treatment resistance, intolerance due to adverse events, and a lack of adherence which contribute to poor outcomes. As such, many patients require adjunct therapies to proper …
Statins are the mainstay treatment for hyperlipidemia; however, the limitations of statins include treatment resistance, intolerance due to …
American Association of Clinical Endocrinology Clinical Practice Guideline on Pharmacologic Management of Adults With Dyslipidemia.
Patel SB, Wyne KL, Afreen S, Belalcazar LM, Bird MD, Coles S, Marrs JC, Peng CC, Pulipati VP, Sultan S, Zilbermint M. Patel SB, et al. Endocr Pract. 2025 Feb;31(2):236-262. doi: 10.1016/j.eprac.2024.09.016. Endocr Pract. 2025. PMID: 39919851
OBJECTIVE: To review the evidence and provide updated and new recommendations for the pharmacologic management of adults with dyslipidemia to prevent adverse cardiovascular outcomes. These recommendations are intended for use by clinicians, health care team members, …
OBJECTIVE: To review the evidence and provide updated and new recommendations for the pharmacologic management of adults with dyslipidemia t …
Triglyceride Lowering Drugs.
Feingold KR. Feingold KR. 2026 Apr 23. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. 2026 Apr 23. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. PMID: 28402615 Free Books & Documents. Review.
The enthusiasm for niacin has greatly decreased with the failure of AIM-HIGH and HPS-2 Thrive to decrease cardiovascular events when niacin was added to statin therapy. ...Numerous studies of low dose omega-3-fatty acids on cardiovascular outcomes …
The enthusiasm for niacin has greatly decreased with the failure of AIM-HIGH and HPS-2 Thrive to decrease cardiovascular event …
Lipoprotein(a) and panvascular disease.
Xu R, Wang Z, Dong J, Yu M, Zhou Y. Xu R, et al. Lipids Health Dis. 2025 May 24;24(1):186. doi: 10.1186/s12944-025-02600-y. Lipids Health Dis. 2025. PMID: 40413492 Free PMC article. Review.
Elevated Lp(a) levels are associated with increased cardiovascular and cerebrovascular event risk, even after controlling for traditional risk factors. ...Furthermore, sex-based differences in Lp(a)-associated risk, response to therapy, and biological behavior are discusse …
Elevated Lp(a) levels are associated with increased cardiovascular and cerebrovascular event risk, even after controlling for traditi …
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.
Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, Sabatine MS. Silverman MG, et al. JAMA. 2016 Sep 27;316(12):1289-97. doi: 10.1001/jama.2016.13985. JAMA. 2016. PMID: 27673306
OBJECTIVE: To evaluate the association between lowering LDL-C and relative cardiovascular risk reduction across different statin and nonstatin therapies. DATA SOURCES AND STUDY SELECTION: The MEDLINE and EMBASE databases were searched (1966-July 2016). ...DATA EXTRACTION A …
OBJECTIVE: To evaluate the association between lowering LDL-C and relative cardiovascular risk reduction across different statin and …
Diabetic dyslipidemia.
Wu L, Parhofer KG. Wu L, et al. Metabolism. 2014 Dec;63(12):1469-79. doi: 10.1016/j.metabol.2014.08.010. Epub 2014 Aug 29. Metabolism. 2014. PMID: 25242435 Review.
Lifestyle modification and glucose control may improve the lipid profile but statin therapy mediates the biggest benefit with respect to cardiovascular risk reduction. Therefore most diabetic patients should receive statin therapy. The role of other lipid low …
Lifestyle modification and glucose control may improve the lipid profile but statin therapy mediates the biggest benefit with respect …
Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies.
Alhomoud IS, Talasaz A, Mehta A, Kelly MS, Sisson EM, Bucheit JD, Brown R, Dixon DL. Alhomoud IS, et al. Pharmacotherapy. 2023 Oct;43(10):1051-1063. doi: 10.1002/phar.2851. Epub 2023 Jul 26. Pharmacotherapy. 2023. PMID: 37464942 Review.
Due to its prothrombotic and proinflammatory properties, Lp(a) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis. Lp(a) levels are genetically determined, and it is estimated that 20%-25% of the global population has …
Due to its prothrombotic and proinflammatory properties, Lp(a) is an independent risk factor for atherosclerotic cardiovascular disea …
Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis.
D'Andrea E, Hey SP, Ramirez CL, Kesselheim AS. D'Andrea E, et al. JAMA Netw Open. 2019 Apr 5;2(4):e192224. doi: 10.1001/jamanetworkopen.2019.2224. JAMA Netw Open. 2019. PMID: 30977858 Free PMC article.
STUDY SELECTION: The systematic review included clinical trials involving niacin as a treatment for cardiovascular disease. The meta-analysis included randomized clinical trials reporting niacin's effect, as exposure, on at least 1 long-term cardiov …
STUDY SELECTION: The systematic review included clinical trials involving niacin as a treatment for cardiovascular disease. Th …
Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
Xie S, Galimberti F, Olmastroni E, Carugo S, Catapano AL, Casula M; META-LIPID Group. Xie S, et al. Atherosclerosis. 2025 Sep;408:120420. doi: 10.1016/j.atherosclerosis.2025.120420. Epub 2025 Jul 3. Atherosclerosis. 2025. PMID: 40618457
BACKGROUND AND AIMS: Lipoprotein (a) [Lp(a)] is an independent and causal risk factor for atherosclerotic cardiovascular disease. In this study we aimed at assessing the effect of currently available lipid-lowering therapies (LLTs) on Lp(a) plasma levels. ...CONCLUS …
BACKGROUND AND AIMS: Lipoprotein (a) [Lp(a)] is an independent and causal risk factor for atherosclerotic cardiovascular disease. In …
368 results